Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 1,125 shares traded hands during mid-day trading, an increase of 41% from the previous session’s volume of 796 shares.The stock last traded at $20.1150 and had previously closed at $19.9460.
Hikma Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.06 and a current ratio of 1.82. The firm has a 50 day simple moving average of $19.22 and a two-hundred day simple moving average of $19.39.
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.
Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.
Featured Stories
- Five stocks we like better than Hikma Pharmaceuticals
- Netflix Stock Is Near 2021 Levels, and Bulls See 4 Reasons to Care
- Tesla Stock Surges 15% as FSD Update Backs Its Autonomy Thesis
- Is the Memory Rally Still Alive After the Semiconductor Sell-Off?
- AirJoule Unveils Prime System, Clearing Path to Commercialization
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
